Kuwait
Tuberculosis profile
Population  2012 3.3 million
Estimates of TB burden * 2012 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.031 (0.03–0.031) 0.94 (0.93–0.95)
Mortality (HIV+TB only) <0.01 (0–<0.01) 0.01 (0–0.04)
Prevalence  (includes HIV+TB) 1.1 (0.36–2.1) 33 (11–65)
Incidence  (includes HIV+TB) 0.85 (0.74–0.96) 26 (23–30)
Incidence (HIV+TB only) <0.01 (<0.01–<0.01) 0.02 (0–0.09)
Case detection, all forms (%) 87 (77–99)    
TB case notifications 2012        
New cases   (%) Retreatment cases (%)
Smear-positive 328 (45) Relapse 0  
Smear-negative 140 (19) Treatment after failure 0  
Smear-unknown / not done 0 (0) Treatment after default 0  
Extrapulmonary 269 (36) Other 0  
Other 0 (0)      
Total new 737   Total retreatment 0  
           
Other (history unknown) 0        
Total new and relapse 737   Total cases notified 737  
New cases Smear-positive Smear-negative/ unknown/
not done
Extrapulmonary
M:F ratio 1.1 1.6 0.9
Age < 15 3 4 17
Laboratories 2012
Smear (per 100 000 population) 0.4
Culture (per 5 million population) 1.5
Drug susceptibility testing (per 5 million population) 1.5
Is second-line drug susceptibility testing available? No
Treatment success rate 2011 (%)        
New smear-positive and/or culture-positive 93   Is rifampicin used
throughout treatment for
new patients?
Yes
New smear-negative/extrapulmonary 84  
Retreatment    
TB/HIV 2012 Number (%)
TB patients with known HIV status 737 (100)
HIV-positive TB patients 3 (<1)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 3 (100)
HIV-positive TB patients on antiretroviral therapy (ART) 3 (100)
HIV-positive people screened for TB    
HIV-positive people provided with IPT    
Estimates of MDR-TB burden 2012*   New   Retreatment
% of TB cases with MDR-TB 0 (0–1.3) 0 (0–98)
MDR-TB cases among notified pulmonary
TB cases
0 (0–6) 0 (0–0)
Reported cases of MDR-TB 2012 New Retreatment Total
Cases tested for MDR-TB      
Laboratory-confirmed MDR-TB cases 4 0 4
Patients started on MDR-TB treatment     4
Financing TB control 2013
National TB programme budget (US$ millions) 7
% Funded domestically 100%
% Funded internationally 0%
% Unfunded 0%
***
(Rate per 100 000 population per year)
Mortality graph
___ Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
___ Prevalence

(Rate per 100 000 population per year)
Incidence graph
__ Notifications Incidence
___
___ Incidence (HIV+TB only)

Treatment success rate (%)
tx success graph
__ New smear-positive and/or culture-positive
__ New smear-negative/extrapulmonary __
Retreatment

(Number of patients)
CPT ART graph
__ HIV-positive TB patients
__ on CPT __ on ART

Total budget (US$ millions)
Budget funding Graph
__ Funded domestically __ Funded internationally
__ Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 * Ranges represent uncertainty intervals Generated: 2014-04-24 Data: www.who.int/tb/data